# Pharmaceutical goods (HS4 3006) Trade Overview | Yugalinks

> Published by **Yugalinks**, global trade intelligence for growing businesses.
>
> [Follow Yugalinks on LinkedIn](https://in.linkedin.com/company/yugalinks)

Pharmaceutical goods at HS4 3006, with reported global trade through 2024.

Canonical: https://www.yugalinks.com/trade/sector/hs4/3006

## Explore Yugalinks

- [Open the trade workspace](https://www.yugalinks.com/app)
- [Read the methodology](https://www.yugalinks.com/methodology)
- [Review data sources](https://www.yugalinks.com/data-sources)
- [Check data coverage](https://www.yugalinks.com/data-coverage)
- [Read Responsible AI principles](https://www.yugalinks.com/responsible-ai)

## Answer

The pharmaceutical goods subsector recorded $20.9B in reported global trade in 2024, with +1.4% annual change.

## Key figures

| Measure | Value |
| --- | --- |
| Latest reported trade | $20.9B |
| Latest annual change | +1.4% |
| Active exporters | 183 |
| Active importers | 200 |
| Active HS6 products | 9 |

## Annual trend

| Year | Global trade | Corridors | HS6 products |
| --- | ---: | ---: | ---: |
| 1995 | $6.0B | 5,038 | 9 |
| 1996 | $6.5B | 5,417 | 9 |
| 1997 | $6.8B | 5,514 | 9 |
| 1998 | $7.1B | 5,582 | 9 |
| 1999 | $8.1B | 5,908 | 9 |
| 2000 | $8.6B | 6,904 | 9 |
| 2001 | $9.2B | 7,046 | 9 |
| 2002 | $5.1B | 5,971 | 9 |
| 2003 | $6.1B | 6,072 | 9 |
| 2004 | $7.3B | 6,241 | 9 |
| 2005 | $8.2B | 6,404 | 9 |
| 2006 | $8.8B | 6,581 | 9 |
| 2007 | $10.4B | 6,573 | 9 |
| 2008 | $12.5B | 6,393 | 9 |
| 2009 | $12.8B | 6,504 | 9 |
| 2010 | $13.1B | 6,483 | 9 |
| 2011 | $14.1B | 6,697 | 9 |
| 2012 | $14.6B | 6,742 | 9 |
| 2013 | $15.1B | 6,763 | 9 |
| 2014 | $15.6B | 7,003 | 9 |
| 2015 | $14.4B | 7,082 | 9 |
| 2016 | $14.2B | 7,135 | 9 |
| 2017 | $14.7B | 7,263 | 9 |
| 2018 | $16.9B | 7,335 | 9 |
| 2019 | $17.5B | 7,394 | 9 |
| 2020 | $16.4B | 7,268 | 9 |
| 2021 | $18.5B | 7,475 | 9 |
| 2022 | $18.6B | 7,852 | 9 |
| 2023 | $20.0B | 7,800 | 9 |
| 2024 | $20.9B | 7,789 | 9 |

## Leading corridors

- Ireland to Netherlands: $1.2B; growth +39.3%.
- Netherlands to USA, Puerto Rico and US Virgin Islands: $472.8M; growth -10%.
- Germany to USA, Puerto Rico and US Virgin Islands: $461.4M; growth +3.8%.
- Germany to Belgium: $388.5M; growth +0.9%.
- Finland to USA, Puerto Rico and US Virgin Islands: $388.4M; growth -3.6%.
- USA, Puerto Rico and US Virgin Islands to China: $351.0M; growth +11.1%.
- Germany to China: $324.2M; growth -7.1%.
- Switzerland, Liechtenstein to Germany: $305.9M; growth +12.6%.
- Germany to Austria: $279.2M; growth +2%.
- China to USA, Puerto Rico and US Virgin Islands: $251.7M; growth -11.9%.

## HS6 products

- Pharmaceutical goods: sterile surgical catgut, suture materials, tissue adhesives, laminaria, laminaria tents, absorbable surgical or dental haemostatics, and surgical or dental adhesion barriers (HS6 300610)
- Pharmaceutical goods: blood-grouping reagents (HS6 300620)
- Pharmaceutical goods: opacifying preparations for x-ray examinations, diagnostic reagents designed to be administered to the patient (HS6 300630)
- Pharmaceutical goods: dental cements and other dental fillings, bone reconstruction cements (HS6 300640)
- Pharmaceutical goods: first aid boxes and kits (HS6 300650)
- Pharmaceutical goods: chemical contraceptive preparations based on hormones or spermicides (HS6 300660)
- Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments (HS6 300670)
- Pharmaceutical goods: waste pharmaceuticals (HS6 300680)
- Pharmaceutical goods: appliances identifiable for ostomy use (HS6 300691)
- Pharmaceutical goods: waste pharmaceuticals (HS6 300692)
- Pharmaceutical goods: placebos and blinded (or double-blinded) clinical trial kits for a recognised clinical trial, put up in measured doses (HS6 300693)

## Definitions and coverage

Merchandise trade observations aggregated to HS4. Growth, concentration, volatility, and peak comparisons calculated from reported observations. Missing values remain unavailable and are not imputed.

Reported observations cover 1995-2024.

## Continue your research

- [Explore HS4 3006 in the workspace](https://www.yugalinks.com/app?hs=3006)
- [Open the Yugalinks workspace](https://www.yugalinks.com/app)

## Other formats

- [HTML](https://www.yugalinks.com/trade/sector/hs4/3006/index.html)
- [JSON](https://www.yugalinks.com/trade/sector/hs4/3006/index.json)
- [JSON-LD](https://www.yugalinks.com/trade/sector/hs4/3006/index.ld.json)


## Continue your research

- [Explore HS4 3006 in the workspace](https://www.yugalinks.com/app?hs=3006)
- [Open the Yugalinks workspace](https://www.yugalinks.com/app)

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-27). [OECD Data Explorer](https://data-explorer.oecd.org/) · [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) · [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) · [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.